Drugs / Wharton Jelly derived Mesenchymal Stem Cells
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT03866330 Comparator | Mar → Dec 2019 | osteoarthritis, hip, osteoarthritis, knee | Medical University of Warsaw | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Wharton Jelly derived Mesenchymal Stem Cells | “Wharton Jelly derived Mesenchymal Stem Cells (WJMSC)” NCT03866330 ↗ |
| Known as | WJMSC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03866330 ↗ |
| Modality | Cell therapy | “Wharton Jelly derived Mesenchymal Stem Cells (WJMSC)” NCT03866330 ↗ |
| Route | Other | “via ultrasound guided intra-articular injection” NCT03866330 ↗ |